Stay updated on Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    - The page no longer shows the 'Melanoma' condition and the 'MedlinePlus Genetics' related topics section.
    Difference
    0.2%
    Check dated 2025-12-31T00:34:12.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Footer updated to Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 were removed.
    Difference
    0.1%
    Check dated 2025-12-23T22:07:56.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    41 days ago
    Change Detected
    Summary
    Melanoma and MedlinePlus Genetics were added as related topics, and publication descriptions were updated with revised wording. These are minor editorial updates to the study page.
    Difference
    0.3%
    Check dated 2025-11-25T11:36:28.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Removal of the government funding/operating-status notice at the top of the page. The study details and other content are unaffected.
    Difference
    0.4%
    Check dated 2025-11-18T07:17:56.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    Deleted topics: Melanoma and MedlinePlus Genetics. This reduces the disease-specific context and related resources available on the page.
    Difference
    0.2%
    Check dated 2025-11-11T03:06:03.000Z thumbnail image
  8. Check
    62 days ago
    Change Detected
    Summary
    Both screenshots show the same study page for NCT01866319, with pembrolizumab vs ipilimumab in advanced melanoma and identical trial details. The changes appear to be cosmetic UI/layout adjustments, not alterations to the study design, eligibility criteria, or reported outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T21:25:38.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.